针对暴发性再生障碍性贫血患者的前期UCBT后原发性移植物衰竭,短期以melphalan为基础的低强度调节补救性UCBT。

Blood cell therapy Pub Date : 2025-03-28 eCollection Date: 2025-05-25 DOI:10.31547/bct-2024-023
Mari Morita-Fujita, Tomohiro Yabushita, Satoshi Yoshioka, Nobuhiro Hiramoto, Takayuki Ishikawa
{"title":"针对暴发性再生障碍性贫血患者的前期UCBT后原发性移植物衰竭,短期以melphalan为基础的低强度调节补救性UCBT。","authors":"Mari Morita-Fujita, Tomohiro Yabushita, Satoshi Yoshioka, Nobuhiro Hiramoto, Takayuki Ishikawa","doi":"10.31547/bct-2024-023","DOIUrl":null,"url":null,"abstract":"<p><p>Umbilical cord blood transplantation (UCBT) is a potential option for patients with very severe aplastic anemia (VSAA) when no suitable related or unrelated donor is available. However, the high incidence of graft failure following UCBT remains a major challenge. The optimal conditioning regimen for UCBT in aplastic anemia (AA), particularly for salvage UCBT after graft failure following an initial transplant, remains undetermined. We report the cases of two adolescent patients with fulminant aplastic anemia who successfully underwent salvage UCBT, conditioned by a short-term melphalan-based regimen for primary graft failure after initial UCBT. The regimen comprised fludarabine (30 mg/m<sup>2</sup>) on days -4 to -2, melphalan (40 mg/m<sup>2</sup>) on days -3 and -2, and total body irradiation (2 Gy) on day -1. Neutrophil engraftment occurred in both cases approximately three weeks after salvage UCBT. One patient developed grade 1 acute graft-versus-host disease (GVHD) and mild chronic GVHD, while the other experienced no GVHD. Both patients have normal complete blood counts more than two years after salvage UCBT. These cases suggest that a short-term melphalan-based regimen may be a viable conditioning option for salvage UCBT in cases of primary graft failure.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 2","pages":"190-194"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138231/pdf/","citationCount":"0","resultStr":"{\"title\":\"Salvage UCBT with Short-Term Melphalan-based Reduced-Intensity Conditioning for Primary Graft Failure after Upfront UCBT for Fulminant Aplastic Anemia.\",\"authors\":\"Mari Morita-Fujita, Tomohiro Yabushita, Satoshi Yoshioka, Nobuhiro Hiramoto, Takayuki Ishikawa\",\"doi\":\"10.31547/bct-2024-023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Umbilical cord blood transplantation (UCBT) is a potential option for patients with very severe aplastic anemia (VSAA) when no suitable related or unrelated donor is available. However, the high incidence of graft failure following UCBT remains a major challenge. The optimal conditioning regimen for UCBT in aplastic anemia (AA), particularly for salvage UCBT after graft failure following an initial transplant, remains undetermined. We report the cases of two adolescent patients with fulminant aplastic anemia who successfully underwent salvage UCBT, conditioned by a short-term melphalan-based regimen for primary graft failure after initial UCBT. The regimen comprised fludarabine (30 mg/m<sup>2</sup>) on days -4 to -2, melphalan (40 mg/m<sup>2</sup>) on days -3 and -2, and total body irradiation (2 Gy) on day -1. Neutrophil engraftment occurred in both cases approximately three weeks after salvage UCBT. One patient developed grade 1 acute graft-versus-host disease (GVHD) and mild chronic GVHD, while the other experienced no GVHD. Both patients have normal complete blood counts more than two years after salvage UCBT. These cases suggest that a short-term melphalan-based regimen may be a viable conditioning option for salvage UCBT in cases of primary graft failure.</p>\",\"PeriodicalId\":72423,\"journal\":{\"name\":\"Blood cell therapy\",\"volume\":\"8 2\",\"pages\":\"190-194\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138231/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood cell therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31547/bct-2024-023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/25 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31547/bct-2024-023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/25 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

脐带血移植(UCBT)是非常严重再生障碍性贫血(VSAA)患者在没有合适的亲属或非亲属供体时的潜在选择。然而,UCBT术后移植失败率高仍然是一个主要挑战。再生障碍性贫血(AA)的UCBT的最佳调理方案,特别是在初次移植后移植失败后的补救性UCBT,仍未确定。我们报告了两例青少年暴发性再生障碍性贫血患者,他们成功地接受了补救性UCBT,在最初的UCBT后,以短期melphalan为基础的方案治疗原发性移植物失败。该方案包括氟达拉滨(30 mg/m2),第4天至第2天,美法兰(40 mg/m2),第3天和第2天,第1天全身照射(2 Gy)。两例患者均在补救性UCBT后约三周出现中性粒细胞植入。一名患者出现了1级急性移植物抗宿主病(GVHD)和轻度慢性移植物抗宿主病,而另一名患者没有发生GVHD。两名患者在补救性UCBT后两年多全血细胞计数正常。这些病例表明,在原发性移植物失败的情况下,短期以美尔芬为基础的方案可能是救救性UCBT的可行调节选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Salvage UCBT with Short-Term Melphalan-based Reduced-Intensity Conditioning for Primary Graft Failure after Upfront UCBT for Fulminant Aplastic Anemia.

Salvage UCBT with Short-Term Melphalan-based Reduced-Intensity Conditioning for Primary Graft Failure after Upfront UCBT for Fulminant Aplastic Anemia.

Umbilical cord blood transplantation (UCBT) is a potential option for patients with very severe aplastic anemia (VSAA) when no suitable related or unrelated donor is available. However, the high incidence of graft failure following UCBT remains a major challenge. The optimal conditioning regimen for UCBT in aplastic anemia (AA), particularly for salvage UCBT after graft failure following an initial transplant, remains undetermined. We report the cases of two adolescent patients with fulminant aplastic anemia who successfully underwent salvage UCBT, conditioned by a short-term melphalan-based regimen for primary graft failure after initial UCBT. The regimen comprised fludarabine (30 mg/m2) on days -4 to -2, melphalan (40 mg/m2) on days -3 and -2, and total body irradiation (2 Gy) on day -1. Neutrophil engraftment occurred in both cases approximately three weeks after salvage UCBT. One patient developed grade 1 acute graft-versus-host disease (GVHD) and mild chronic GVHD, while the other experienced no GVHD. Both patients have normal complete blood counts more than two years after salvage UCBT. These cases suggest that a short-term melphalan-based regimen may be a viable conditioning option for salvage UCBT in cases of primary graft failure.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信